News J&J says 2026 sales could top $100 billion J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.
News NICE backs Roche lupus drug that supports kidney function Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.
News 11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
News EU approves Otsuka's long-acting HAE drug Dawnzera An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.
News ImmunityBio rises as route opens to broader Anktiva label Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.
News ViiV ownership shifts as Pfizer sells its stake Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.
News Two more biotechs, Attovia and Braveheart, join the IPO line The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.